NeuroSense Therapeutics Ltd.

NasdaqCM:NRSN Stock Report

Market Cap: US$17.5m

NeuroSense Therapeutics Balance Sheet Health

Financial Health criteria checks 3/6

NeuroSense Therapeutics has a total shareholder equity of $-1.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.8M and $3.5M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$1.21m
Equity-US$1.70m
Total liabilitiesUS$3.54m
Total assetsUS$1.84m

Recent financial health updates

NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely

Mar 22
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely

Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?

Dec 06
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

Mar 03
Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

Recent updates

NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely

Mar 22
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely

Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?

Dec 06
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

Mar 03
Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

Nov 17
Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

NeuroSense Therapeutics GAAP EPS of -$0.55

Aug 31

We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Jul 06
We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

NeuroSense climbs 66% after early data supporting Alzheimer’s candidate

Jun 30

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

Mar 31

NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

Mar 22
NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

Dec 22

Financial Position Analysis

Short Term Liabilities: NRSN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NRSN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NRSN is debt free.

Reducing Debt: NRSN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NRSN has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: NRSN is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies